文献速递胰腺与胆道疾病

囊性纤维化跨膜传导调节因子调节剂的使用与囊性纤维化患者胰腺炎住院减少相关

Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis.
PubMed 文献 · Am J Gastroenterol · 2021-01-01

本研究基于MarketScan数据库2012-2018年数据,纳入10417例囊性纤维化(CF)患者,其中1795例接受CFTR调节剂治疗。胰腺功能不全(PI)患者急性胰腺炎(AP)发生率低于胰腺功能足够(PS)患者(0.9% vs 2.9%,P=0.007)。使用CFTR调节剂期间,PS-CF患者AP住院率比为0.33(95%CI 0.10-1.11,P=0.07),PI-CF患者为0.38(95%CI 0.16-0.89,P=0.03),分别相对降低67%和62%。

要点

  • CFTR调节剂使用与CF患者急性胰腺炎住院减少相关,PI-CF中差异有统计学意义。
  • PS-CF患者AP发生率高于PI-CF(2.9% vs 0.9%,P=0.007)。
  • 需前瞻性研究验证CFTR调节剂降低AP住院的作用。

核心结论

  • CFTR调节剂的使用与囊性纤维化患者急性胰腺炎住院减少相关。
  • 观察性数据支持开展前瞻性研究以验证CFTR调节剂减少AP住院的效果。

研究设计与样本

  • 基于MarketScan(2012-2018)数据库的回顾性队列研究,查询CF患者中AP住院和CFTR调节剂使用情况。
  • 共识别10417例CF患者,其中1795例接受了CFTR调节剂治疗。
  • 采用多变量Poisson模型分析使用与未使用CFTR调节剂期间AP住院率,模型允许治疗组间交叉。
  • 胰腺功能不全定义为使用胰腺酶替代治疗。

主要发现

  • PS-CF患者AP发生率高于PI-CF(2.9% vs 0.9%,P=0.007)。
  • 总体使用CFTR调节剂期间,PS-CF的AP住院率比为0.33(95%CI 0.10-1.11,P=0.07),PI-CF为0.38(95%CI 0.16-0.89,P=0.03)。
  • 上述率比分别对应PS-CF和PI-CF中AP住院相对减少67%和62%。
  • 在1795例均有CFTR调节剂使用史的患者亚组分析中,PS-CF的AP住院率比为0.36(95%CI 0.13-1.01,P=0.05),PI-CF为0.53(95%CI 0.18-1.58,P=0.26)。

临床怎么用

  • 对于囊性纤维化患者,使用CFTR调节剂可能降低急性胰腺炎住院风险,尤其应关注胰腺功能不全患者中的统计学显著关联。
  • 临床决策中可参考此观察性证据,但需结合个体情况并等待前瞻性研究进一步验证。

局限性

  • 本研究为观察性研究,可能存在未测量的混杂因素。
  • 胰腺功能不全仅通过胰腺酶替代治疗使用来定义,可能存在错分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Acute pancreatitis (AP) occurs among patients with pancreas-sufficient cystic fibrosis (PS-CF) but is reportedly less common among patients with pancreas-insufficient cystic fibrosis (PI-CF). The incidence of AP may be influenced by cystic fibrosis transmembrane conductance regulator (CFTR) modulator use. We hypothesized that CFTR modulators would reduce AP hospitalizations, with the greatest benefit in PS-CF. METHODS: MarketScan (2012-2018) was queried for AP hospitalizations and CFTR modulator use among patients with CF. Multivariable Poisson models that enabled crossover between CFTR modulator treatment groups were used to analyze the rate of AP hospitalizations on and off therapy. Pancreas insufficiency was defined by the use of pancreas enzyme replacement therapy. RESULTS: A total of 10,417 patients with CF were identified, including 1,795 who received a CFTR modulator. AP was more common in PS-CF than PI-CF (2.9% vs 0.9%, P = 0.007). Overall, the observed rate ratio of AP during CFTR modulator use was 0.33 (95% confidence interval [CI] 0.10, 1.11, P = 0.07) for PS-CF and 0.38 (95% CI 0.16, 0.89, P = 0.03) for PI-CF, indicating a 67% and 62% relative reduction in AP hospitalizations, respectively. In a subset analysis of 1,795 patients who all had some CFTR modulator use, the rate ratio of AP during CFTR modulator use was 0.36 (95% CI 0.13, 1.01, P = 0.05) for PS-CF and 0.53 (95% CI 0.18, 1.58, P = 0.26) for PI-CF. DISCUSSION: CFTR modulator use is associated with a reduction in AP hospitalizations among patients with CF. These observational data support the prospective study of CFTR modulators to reduce AP hospitalizations among patients with CF.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Ramsey ML, Gokun Y, Sobotka LA, et al. Cystic Fibrosis Transmembrane Conductance Regulator Modulator Use Is Associated With Reduced Pancreatitis Hospitalizations in Patients With Cystic Fibrosis. Am J Gastroenterol. 2021. PMID: 34665155. doi:10.14309/ajg.0000000000001527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。